RDATE:13032009

StandoutStocks.com "Stocks that Standout" picks for today are: Accenture (NYSE: ACN), DOR BioPharma, Inc. (OTCBB: DORB), Universal Detection Technology (OTCBB: UNDT), United Technologies Corp. (NYSE: UTX)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Accenture (NYSE: ACN) has extended for two additional years its contract to provide RSA UK with insurance business process outsourcing (BPO) services.

Under the original contract, signed in 2003, RSA outsourced to Accenture front-line customer service as well as back-office administration services across RSA's sales, service, claims and customer accounting functions, supporting direct, affinity and broker customers. The initial agreement was scheduled to expire in 2010, and under terms of the agreement, Accenture will continue to provide these services through 2012.

"We extended our relationship with Accenture based on their history of delivering impressive results and their expertise in insurance, which enables them to understand the complexity of our business," said Bill Taylor, COO, Sales and Service and Head of BPO Strategy of RSA. "In addition to cost reductions, RSA is benefiting from high service levels, which are essential for customer satisfaction and our future revenue growth."

Deepak Sircar, global lead for Accenture's insurance BPO services, said, "We look forward to continuing to provide high-quality and cost-competitive services to help RSA improve their operational performance, focus on growing their business and continue to deliver excellent service to their customers."

About RSA

With an almost 300 year heritage, RSA is one of the world's leading multinational quoted insurance groups. It has the capability to write business in over 130 countries and with major operations in the UK, Scandinavia, Canada, Ireland, Asia and the Middle East and Latin America. Focusing on general insurance, it has around 22,000 employees and, in 2007, its net written premiums were GBP 5.8bn. Within the UK, RSA is the largest commercial lines insurer, covering the insurance and risk management needs of a significant number of FTSE 100 companies. It has a full multi-distribution capability, writing business through brokers and corporate partners, direct and online. RSA is also one of the UK's top three personal motor and household insurers.

Please enable Javascript

About Accenture

Accenture is a global management consulting, technology services and outsourcing company. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world's most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. With more than 186,000 people serving clients in over 120 countries, the company generated net revenues of US$23.39 billion for the fiscal year ended Aug. 31, 2008.

DOR BioPharma, Inc. (OTCBB: DORB) (DOR or the Company) announced today that it has appointed Brian L. Hamilton, MD, PhD, as Senior Vice President and Chief Medical Officer. Dr. Hamilton is a recognized expert in both the global development of topically active steroids as well as in Graft-versus-Host disease (GVHD) and has had a long and distinguished career of more than 25 years in both academia and industry, most notably at Wyeth and Astra, USA. Dr. Hamilton will lead DOR's clinical affairs, with an emphasis on the execution of its confirmatory Phase 3 clinical trial of orBec(R) (oral beclomethasone dipropionate or BDP) in the treatment of acute GI GVHD.

Dr. Hamilton earned his MD and PhD (Transplantation Immunology) at the University of Washington, Seattle, and trained in Pediatrics, Allergy/Immunology, and Oncology. He began his training in bone marrow transplantation while in medical school, with further training at the Children's Hospital Medical Center, Boston, MA. His academic career, at the University of Washington and the University of Miami, focused on pediatric immunology and bone marrow transplantation. His research focus was in the immunobiology of GVHD in an animal model. He also spent several years as Chief of Immunology at the Children's Hospital, Oakland, CA with a clinical appointment on the Pediatric Bone Marrow Transplant Service at the University of California - San Francisco.

Following his academic career, Dr. Hamilton joined the pharmaceutical industry, initially at Astra, USA in Westborough, MA working on inhaled steroids (Rhinocort Aqua and Pulmicort Turbuhaler) for the treatment of allergic rhinitis and asthma, including three successful new drug applications for these products. He has worked with several pharmaceutical and biotechnology companies including Alkermes in multiple therapeutic areas, including allergy, asthma, oncology, rheumatology, hematology, diagnostics, and drug delivery systems.

"As I join the DOR team in the ongoing development of orBec(R) and the other exciting portfolio compounds, I look forward to applying my experience in drug development to my long-standing commitment to improving the lives of patients with GVHD," stated Brian L. Hamilton, MD, PhD, Chief Medical Officer of DOR.

"We are very pleased to welcome Dr. Hamilton to the DOR team," said Christopher J. Schaber, PhD, President and CEO of DOR. "We could not ask for someone whose skill set provides a better fit to lead our clinical programs forward. His experience in successfully developing Rhinocort Aqua and Pulmicort Turbuhaler (topical budesonide, the active ingredient in Entocort) while at Astra will be instrumental to us as we advance orBec(R) to Phase 3 completion in GI GVHD. His specific expertise in GVHD will be vital to the successful interaction between DOR and the Phase 3 clinical sites in our upcoming confirmatory trial. With Dr. Hamilton's demonstrated record of advancing products through clinical development to commercial success, we are enthusiastically looking forward to expeditiously completing our Phase 3 clinical trial, while continuing to expand and build our pipeline."

Please enable Javascript

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the first half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today that it has received a purchase order for its five-agent bioterrorism detection Equipment from the Miami-Dade Police Department. The Equipment is capable of spot detection of anthrax, ricin toxin, botulinum toxin, plague, and SEBs. The purchase order also includes kits that mimic a "suspicious powder" scenario thus preparing the first responders for a real world event.

The Miami-Dade Police Department (MDPD) is the largest police department in the Southeastern United States, with approximately 4,500 employees. The MDPD has a dedicated anti-terror unit with officers specializing in biological and chemical warfare detection methods.

UNDT's 5-agent detection equipment has been extensively used by first responders and private industry throughout the country. The equipment has been evaluated by the U.S. DOD as well as the United Kingdom military. The equipment's capacities include:

* No cross-reactivity with near neighbor strains

* No cross-reactivity to household powders

* No set up time

* No expensive reader needed

* No decontamination requirements

Please enable Javascript

* No false positives

* No false negatives

* No hook effect

"This is the second order for our equipment from a major metropolitan first responder agency in the last few months," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer. "We will continue to expand the marketing of our detection equipment in the coming year," he added.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.

Sikorsky Aircraft Corp., a subsidiary of United Technologies Corp. (NYSE: UTX), today announced the successful demonstration of technology designed to enable safer helicopter landings in blinding conditions including brownouts. Sikorsky and its Sandblaster project teammates, including Honeywell International and Sierra Nevada Corp., performed the demonstrations at the U.S. Army Aeroflightdynamics Directorate (AFDD), AMRDEC at Ames Research Center, Moffett Field, Calif.

Flying the RASCAL JUH-60 BLACK HAWK helicopter outfitted with the prototype Sandblaster system, pilots executed landing approaches Jan. 12-14 in a variety of terrain, including slopes containing potentially dangerous obstacles to safe landings. With only a few hours of familiarization with the system, guest pilots executed the approaches safely. The flight demonstration team included three U.S. Army pilots, and ground observers included personnel from several Army, Air Force and Marine Corps' technology development offices.

In May 2007, Sikorsky announced a contract award from the Defense Advanced Research Projects Agency (DARPA) to develop and demonstrate a system for guiding safer landings in situations where pilots cannot see the ground due to degraded visibility. Brownouts, for example, occur frequently in desert environments when rotor downwash kicks up sand and dust into blinding clouds enveloping the aircraft.

"The Sandblaster project speaks to Sikorsky's strength and priority, which is engineering safety into products," said Brad Kronauer, Sandblaster Program Manager. "As the system integrator, we commend our Honeywell and Sierra Nevada teammates for their efforts in making these demonstrations so successful, proving these combined technologies work together as a prototype system, and allowing us to move toward development of a system for production."

The system integrates several technologies, including advanced flight controls, a "see-through" sensor, advanced synthetic vision, and data fusion, allowing the pilot to locate and touch down on level landing terrain free of obstacles.

Please enable Javascript

Using the system, a pilot presses a single button to engage the automated flight controls, developed by Sikorsky. These controls bring the aircraft from en-route flight to a low hover with little-to-no drifting over a pre-programmed landing point. During the landing approach, Sierra Nevada's three-dimensional radar, capable of penetrating sand and dust, detects terrain and objects within the intended landing zone. Using radar and other data, Honeywell's Sensor-driven Localized External Evidential Knowledge (SLEEK) and Synthetic Vision System (SVS) displays on a cockpit screen a three-dimensional view of the landing zone and surroundings. The pilot is able to monitor progress during the automated approach by viewing an electronic representation of the landing zone. The pilot also is able to view and adjust the precise landing point in relation to slopes and other objects while the automated flight controls maintain stability. The system includes a 360-degree view of terrain and objects in relation to the intended landing point.

Sikorsky Aircraft Corp., based in Stratford, Conn., is a world leader in helicopter design, manufacture, and service. The company's long commitment to safety and innovation is reflected in its mission statement: "We pioneer flight solutions that bring people home everywhere ... every time(TM)."

United Technologies Corp., based in Hartford, Conn., provides a broad range of high-technology products and support services to the aerospace and building systems industries.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Please enable Javascript

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).

This is a news service of Thomson Business Intelligence Service ©2006. This content is for your personal use only, subject to Terms and Conditions. No redistribution allowed.